NASDAQ:OSUR - OraSure Technologies Stock Price, News, & Analysis

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

OraSure Technologies, Inc. (NASDAQ:OSUR) released its quarterly earnings data on Wednesday, August, 8th. The medical instruments supplier reported $0.07 EPS for the quarter, topping the consensus estimate of $0.04 by $0.03. The medical instruments supplier had revenue of $43.60 million for the quarter, compared to analyst estimates of $42.24 million. OraSure Technologies had a net margin of 8.38% and a return on equity of 5.85%. The business's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.09 EPS. View OraSure Technologies' Earnings History.

OraSure Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for OraSure Technologies.

OraSure Technologies updated its third quarter earnings guidance on Wednesday, August, 8th. The company provided earnings per share guidance of $0.10-0.12 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.11. The company issued revenue guidance of $44-45.5 million, compared to the consensus revenue estimate of $43.72 million.

3 brokers have issued 12 month target prices for OraSure Technologies' stock. Their forecasts range from $23.00 to $24.00. On average, they expect OraSure Technologies' share price to reach $23.50 in the next year. This suggests a possible upside of 52.0% from the stock's current price. View Analyst Price Targets for OraSure Technologies.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for OraSure Technologies.

Some companies that are related to OraSure Technologies include NuVasive (NUVA), Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Glaukos (GKOS), Nevro (NVRO), Luminex (LMNX), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), Cryolife (CRY), Tactile Systems Technology (TCMD), AtriCure (ATRC), Atrion (ATRI), K2M Group (KTWO) and SurModics (SRDX).

Media headlines about OSUR stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OraSure Technologies earned a news impact score of 0.18 on Accern's scale. They also gave media headlines about the medical instruments supplier an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for OraSure Technologies.

OraSure Technologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.89%), Renaissance Technologies LLC (6.38%), Dimensional Fund Advisors LP (4.63%), Fred Alger Management Inc. (4.41%), Peregrine Capital Management LLC (1.72%) and Emerald Advisers Inc. PA (1.65%). Company insiders that own OraSure Technologies stock include Anthony Zezzo II, Brian Smith, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Mara G Aspinall, Mark L Kuna, Michael Celano, Ronald H Spair, Ronny B Lancaster and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies.

OSUR stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Fisher Asset Management LLC, Renaissance Technologies LLC, Thompson Siegel & Walmsley LLC, Royce & Associates LP, Citadel Advisors LLC, Voya Investment Management LLC and Wells Fargo & Company MN. Company insiders that have sold OraSure Technologies company stock in the last year include Brian Smith, Charles W Patrick, Douglas A Michels and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies.

OSUR stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., BlackRock Inc., Casdin Capital LLC, Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, American Capital Management Inc., Penn Capital Management Co. Inc. and Bank of America Corp DE. View Insider Buying and Selling for OraSure Technologies.

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OSUR stock can currently be purchased for approximately $15.46.

OraSure Technologies has a market capitalization of $946.35 million and generates $167.06 million in revenue each year. The medical instruments supplier earns $30.94 million in net income (profit) each year or $0.51 on an earnings per share basis. OraSure Technologies employs 377 workers across the globe.

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]